Liquid Biopsy in Paraneoplastic Neurological Syndromes

Liquid Biopsy in Paraneoplastic Neurological Syndromes With High- and Intermediate-Risk Antibodies

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT07491328

Acronym

LiB-PNS

Enrollment

Registered

2026-03-24

Start date

2023-05-20

Completion date

2030-12-30

Last updated

2026-03-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Paraneoplastic Neurological Syndromes

Keywords

Circulating tumor cells (CTCs), Circulating tumor DNA (ctDNA), Diagnostic leukapheresis (DLA)

Brief summary

The main objective of the study is to assess whether circulating tumor cells (CTCs) can be detected in the peripheral blood of patients with paraneoplastic neurological syndromes (PNS) by diagnostic leukapheresis (DLA) combined with the CELLSEARCH® System during clinical routine workup. If CTCs can be identified, a detailed molecular genetic analysis will be performed to characterize mutations in oncogenes and tumor suppressor genes. In addition, the study aims to analyze cell-free DNA (cfDNA) in serum of patients. Individuals with PNS and high- or intermediate-risk or GAD65-antibodies with a detectable tumor (PNS+T), PNS patients with high- or intermediate-risk or GAD65-antibodies without detectable tumor (PNS w/o T), and matched tumor patients without PNS (T w/o PNS) will be included in the study.

Interventions

DIAGNOSTIC_TESTCTC & ctDNA analysis

Analysis of circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA) in the peripheral blood

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Patients with paraneoplastic neurological syndromes (PNS) and high- or intermediate-risk or GAD65-antibodies or * Patients with peripheral tumors without PNS

Exclusion criteria

* Age below 18 years at the time of inclusion. * Any mental condition impairing the capacity to provide informed consent. * Presence of contraindications to DLA.

Design outcomes

Primary

Measure	Time frame	Description
CTC detection	Time of enrollment (BL)	Detection of circulating tumor cells (CTCs) in the peripheral blood
ctDNA detection	Time of enrollment (BL)	Detection of circulating tumor DNA (ctDNA) in serum

Secondary

Measure	Time frame	Description
CTC mutation profile	Time of CTC analysis (BL)	Mutations in oncogenes and tumor suppressor genes

Countries

Germany

Contacts

CONTACTNico Melzer, MD

nico.melzer@med.uni-duesseldorf.de+49-(0)211-81-04170

CONTACTSaskia Räuber, MD

SaskiaJanina.Raeuber@med.uni-duesseldorf.de+49-(0)211-81-04170

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 25, 2026